|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
���รΤ |
|
DNA���� |
|
Ƥ������ |
|
���� |
| ��������������� | |
|
�⽣�� |
|
֣���� |
| PubMed | |
|
Article by |
|
Article by |
���รΤ��ҩ����������Ƥ���Ƶ�Ӧ��
�⽣��, ֣����
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о��� �Ͼ� 210042
���รΤ��һ�־��й���DNA�������Ե���������,��ͨ�����������Ʋ���DNA�ۺ�ø����ֹ����DNA�ĺϳɡ������о���ʾ������յ�ϸ������������Ѫ�����ɵ����á����รΤ�����Ҫ�������ư��̲����ߵľ�ϸ������������Ĥ��,���������Ƽ���ʪ�ࡢ���������Ⱦ������ȶ��ֲ�����Ƥ������Ƥ������Ҳȡ���˽Ϻõ���Ч��
[2] Xiong X, Smith JL, Chen MS. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation.Antimicrob Agents Chemother, 1997, 41:594-599.
[3] Mendel DB, Barkhimer DB, Chen MS. Biochemical basis for increased susceptibility to cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity. Antimicrob Agents Chemother, 1995,39:2120-2122.
[4] Johnson JA, Gangemi JD. Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl]cytosine. Antimicrob Agents Chemother,1999, 43:1198-1205.
[5] Andrei G, Snoeck R, Schols D, et al. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res,2000, 12:397-408.
[6] Liekens S, Neyts J, De Clercq E, et al. Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir. Cancer Res, 2001,61:5057-5064.
[7] Cundy KC, Petty BG, Flaherty J, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother, 1995,39:1247-1252.
[8] Cundy KC, Lynch G, Lee WA. Bioavailability and metabolism of cidofovir following topical administration to rabbits. Antiviral Res,1997, 35:113-122.
[9] Lalezari J, Schacker T, Feinberg J, et al. A randomized, doubleblind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis, 1997, 176:892-898.
[10] Sacks SL, Shafran SD, Diaz-Mitoma F, et al. A multicenter phase ��/�� dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes. Antimicrob Agents Chemother, 1998, 42:2996-2999.
[11] Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest, 1997,99:2082-2086.
[12] Mazzi R, Parisi SG, Sarmati L, et al. Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS. AIDS, 2001,15:2061-2062.
[13] Little RF, Merced-Galindez F, Staskus K, et al. A pilot study of cidofovir in patients with kaposi sarcoma. J Infect Dis, 2003, 187:149-153.
[14] Orlando G, Fasolo MM, Beretta R, et al. Combined surgery and cidofovir is an effective treatment for genital warts in HIV-infected patients. AIDS, 2002, 16:447-450.
[15] Matteelli A, Beltrame A, Graifemberghi S, et al. Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons. Sex Transm Dis, 2001, 28:343-346.
[16] Snoeck R, Bossens M, Parent D, et al. Phase �� double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis, 2001, 33:597-602.
[17] Hivnor C, Shepard JW, Shapiro MS, et al. Intravenous cidofovir for recalcitrant verruca vulgaris in the setting of HIV. Arch Dermatol,2004, 140:13-14.
[18] Snoeck R, Noel JC, Muller C,et al. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade �� (CIN ��). J Med Virol, 2000, 60:205-209.
[19] Preiser W, Kapur N, Snoeck R, et al. No apparent effect of cidofovir in epidermodysplasia verruciformis. J Clin Virol, 2000, 16:55-57.
[20] Calista D. Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV/AIDS. A pilot study. J Eur Acad Dermatol Venereol, 2000, 14:484-488.
[21] Zabawski EJ Jr. A review of topical and intralesional cidofovir. Dermatol Online J, 2000, 6:3.
[22] Calista D. Topical 1% cidofovir for the treatment of basal cell carcinoma. Eur J Dermatol, 2002, 12:562-564.
[23] Calista D. Regression of a cutaneous melanoma metastasis after intralesional cidofovir. Melanoma Res, 2003, 13:205-206.
[24] Bienvenu B, Martinez F, Devergie A, et al. Topical use of cidofovir induced acute renal failure. Transplantation, 2002, 73:661-662.